search
Back to results

Improving Lower Limb Blood Flow in Healthy Adult Volunteers (THRIVE-1)

Primary Purpose

Deep Vein Thrombosis

Status
Completed
Phase
Early Phase 1
Locations
United Kingdom
Study Type
Interventional
Intervention
geko
Sponsored by
Queen Mary University of London
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Deep Vein Thrombosis focused on measuring Deep Vein Thrombosis

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  1. Be in good general health and fitness.
  2. Aged between 18 and 65 years.
  3. Free of significant abnormal findings as determined by medical history (specifically an absence of DVT or haematological disorders or indications), screening physical examination, vital signs (sitting blood pressure, sitting pulse rate, sitting respiratory rate and body temperature) and duplex ultrasound within 48 hours prior to commencement of the each study phase.
  4. BMI between 18 and 34
  5. No history or signs of drug abuse (including alcohol), licit or illicit.
  6. Has not to used any medications (prescribed or over-the-counter including herbal remedies) judged to be significant by the Principal Investigator during the thirty (30) days preceding the study, and agrees not to use any medications during the course of the study without informing the Research Team.
  7. Able to understand the Volunteer Information Sheet and signed the written Informed Consent Forms.
  8. Able and willing to follow the Protocol requirements.

Exclusion Criteria:

  1. Any evidence of organ dysfunction, or any clinically significant deviation from normal in the physical determinations.
  2. History or signs of haematological disorders (especially in relation to clotting or coagulation or previous Deep or superficial vein thrombosis/pulmonary embolism).
  3. Peripheral arterial disease (ABPI < 0.9), varicose veins or lower limb ulceration.
  4. Musculoskeletal disorders (such as pain during exercise of lower limb).
  5. Recent surgery (such as abdominal, gynaecological, hip knee replacement).
  6. Recent trauma to lower limb.
  7. Chronic Obesity (BMI Index >34).
  8. Pregnancy.
  9. Any Medication judged to be significant by the Principal Investigator (such as anticoagulants, agents with significant vasoactive activity, Oestrogen pill, 'morning-after pill' or HRT).
  10. Tobacco consumption
  11. History of disorders of the gastrointestinal, hepatic, renal, cardiovascular, endocrine, neurological, dermatological, rheumatologic, metabolic (including diabetes), psychiatric, haematological (especially in relation to clotting or coagulation), or systemic disease judged to be significant.
  12. A pulse rate of less than 50 beats/minute, a sitting systolic blood pressure >160 or <80 mmHg and/or a sitting diastolic pressure of >90 or <60 mmHg.
  13. Any significant illness during the four (4) weeks preceding the screening period of the study.
  14. Any contraindication to blood sampling.
  15. Donation of blood during the eight (8) weeks preceding the screening period of the study or during the investigation.
  16. Participation in any clinical study during the 8 weeks preceding the dosing period of the study

Sites / Locations

  • St. Bartholomew's Hospital

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Device

Arm Description

Outcomes

Primary Outcome Measures

Changes in blood flow and volume, together with microcirculatory velocity were measured
Changes in blood flow and volume, together with microcirculatory velocity were measured using laser Doppler flowmetry (Laser Doppler Perfusion & Temperature Monitor DRT4; Moor Instruments Ltd, UK) and colour flow duplex ultrasound (Philips IU22; Philips Healthcare, USA).

Secondary Outcome Measures

Full Information

First Posted
November 5, 2013
Last Updated
November 5, 2013
Sponsor
Queen Mary University of London
search

1. Study Identification

Unique Protocol Identification Number
NCT01981733
Brief Title
Improving Lower Limb Blood Flow in Healthy Adult Volunteers
Acronym
THRIVE-1
Official Title
A Study to Determine the Effects of a Novel Method for Improving Lower Limb Blood Flow in Healthy Adult Volunteers
Study Type
Interventional

2. Study Status

Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
March 2005 (undefined)
Primary Completion Date
April 2012 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Queen Mary University of London

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The THRIVE-1 study will examine novel methods for enhancing blood flow in the lower limb using electrical stimulation. Increases in lower limb blood flow improve venous return and thereby reduce venous stasis. Since stasis is one of the compounding factors in the development of deep vein thrombosis, the risk of developing thrombosis should theoretically be proportionally reduced. This technique may prove to be a useful tool in preventing and reducing the incidence of deep vein thrombosis in both medical and surgical patients together with passengers undertaking significant duration travel (as travel - related deep vein thrombosis is not exclusively related to flying).

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Deep Vein Thrombosis
Keywords
Deep Vein Thrombosis

7. Study Design

Primary Purpose
Basic Science
Study Phase
Early Phase 1
Masking
None (Open Label)
Enrollment
50 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Device
Arm Type
Experimental
Intervention Type
Device
Intervention Name(s)
geko
Other Intervention Name(s)
geko TM
Intervention Description
The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
Primary Outcome Measure Information:
Title
Changes in blood flow and volume, together with microcirculatory velocity were measured
Description
Changes in blood flow and volume, together with microcirculatory velocity were measured using laser Doppler flowmetry (Laser Doppler Perfusion & Temperature Monitor DRT4; Moor Instruments Ltd, UK) and colour flow duplex ultrasound (Philips IU22; Philips Healthcare, USA).
Time Frame
30 mins with 10 min washouts

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Be in good general health and fitness. Aged between 18 and 65 years. Free of significant abnormal findings as determined by medical history (specifically an absence of DVT or haematological disorders or indications), screening physical examination, vital signs (sitting blood pressure, sitting pulse rate, sitting respiratory rate and body temperature) and duplex ultrasound within 48 hours prior to commencement of the each study phase. BMI between 18 and 34 No history or signs of drug abuse (including alcohol), licit or illicit. Has not to used any medications (prescribed or over-the-counter including herbal remedies) judged to be significant by the Principal Investigator during the thirty (30) days preceding the study, and agrees not to use any medications during the course of the study without informing the Research Team. Able to understand the Volunteer Information Sheet and signed the written Informed Consent Forms. Able and willing to follow the Protocol requirements. Exclusion Criteria: Any evidence of organ dysfunction, or any clinically significant deviation from normal in the physical determinations. History or signs of haematological disorders (especially in relation to clotting or coagulation or previous Deep or superficial vein thrombosis/pulmonary embolism). Peripheral arterial disease (ABPI < 0.9), varicose veins or lower limb ulceration. Musculoskeletal disorders (such as pain during exercise of lower limb). Recent surgery (such as abdominal, gynaecological, hip knee replacement). Recent trauma to lower limb. Chronic Obesity (BMI Index >34). Pregnancy. Any Medication judged to be significant by the Principal Investigator (such as anticoagulants, agents with significant vasoactive activity, Oestrogen pill, 'morning-after pill' or HRT). Tobacco consumption History of disorders of the gastrointestinal, hepatic, renal, cardiovascular, endocrine, neurological, dermatological, rheumatologic, metabolic (including diabetes), psychiatric, haematological (especially in relation to clotting or coagulation), or systemic disease judged to be significant. A pulse rate of less than 50 beats/minute, a sitting systolic blood pressure >160 or <80 mmHg and/or a sitting diastolic pressure of >90 or <60 mmHg. Any significant illness during the four (4) weeks preceding the screening period of the study. Any contraindication to blood sampling. Donation of blood during the eight (8) weeks preceding the screening period of the study or during the investigation. Participation in any clinical study during the 8 weeks preceding the dosing period of the study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Arthur Tucker, BSc PhD
Organizational Affiliation
St. Bartholomew's Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
St. Bartholomew's Hospital
City
London
ZIP/Postal Code
EC1A 7BE
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

Improving Lower Limb Blood Flow in Healthy Adult Volunteers

We'll reach out to this number within 24 hrs